全文获取类型
收费全文 | 190999篇 |
免费 | 18807篇 |
国内免费 | 7199篇 |
专业分类
耳鼻咽喉 | 1189篇 |
儿科学 | 4491篇 |
妇产科学 | 2681篇 |
基础医学 | 36453篇 |
口腔科学 | 3927篇 |
临床医学 | 11988篇 |
内科学 | 32193篇 |
皮肤病学 | 3236篇 |
神经病学 | 15724篇 |
特种医学 | 3682篇 |
外国民族医学 | 57篇 |
外科学 | 13987篇 |
综合类 | 23764篇 |
现状与发展 | 30篇 |
预防医学 | 8357篇 |
眼科学 | 2239篇 |
药学 | 25640篇 |
20篇 | |
中国医学 | 6705篇 |
肿瘤学 | 20642篇 |
出版年
2024年 | 155篇 |
2023年 | 2866篇 |
2022年 | 3731篇 |
2021年 | 7235篇 |
2020年 | 6704篇 |
2019年 | 7730篇 |
2018年 | 7334篇 |
2017年 | 7234篇 |
2016年 | 7077篇 |
2015年 | 8483篇 |
2014年 | 11873篇 |
2013年 | 13253篇 |
2012年 | 12185篇 |
2011年 | 14454篇 |
2010年 | 12277篇 |
2009年 | 11641篇 |
2008年 | 11046篇 |
2007年 | 9850篇 |
2006年 | 8910篇 |
2005年 | 7593篇 |
2004年 | 6646篇 |
2003年 | 5652篇 |
2002年 | 4364篇 |
2001年 | 3717篇 |
2000年 | 3052篇 |
1999年 | 2638篇 |
1998年 | 2011篇 |
1997年 | 1897篇 |
1996年 | 1568篇 |
1995年 | 1582篇 |
1994年 | 1380篇 |
1993年 | 1163篇 |
1992年 | 965篇 |
1991年 | 867篇 |
1990年 | 714篇 |
1989年 | 599篇 |
1988年 | 513篇 |
1987年 | 415篇 |
1986年 | 422篇 |
1985年 | 797篇 |
1984年 | 821篇 |
1983年 | 576篇 |
1982年 | 645篇 |
1981年 | 509篇 |
1980年 | 418篇 |
1979年 | 365篇 |
1978年 | 280篇 |
1977年 | 221篇 |
1976年 | 206篇 |
1975年 | 142篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Recurrent BRCA1 Mutation,but no BRCA2 Mutation,in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing 下载免费PDF全文
Hoang Anh VuNgo Dai PhuLe Thai KhuongPham Huy HoaBui Thi Hong NhuVo Thanh NhanLe Quang ThanhNguyen Duy SinhHoang Thanh ChiNguyen Dang QuanNguyen Trong Binh 《Asian Pacific journal of cancer prevention》2020,21(8):2331-2335
Background: Identification of germline and somatic BRCA1/2 mutations in ovarian cancer is important for genetic counseling and treatment decision making with poly ADP ribose polymerase inhibitors. Unfortunately, data on the frequency of BRCA1/2 mutations in Vietnamese patients are scare. Methods: We aim to explore the occurrence of BRCA1/2 mutations in 101 Vietnamese patients with ovarian cancer including serous (n = 58), endometrioid (n = 14), mucinous (n = 24), and clear cell (n = 5) carcinomas. BRCA1/2 mutations were detected from formalin-fixed parafin-embedded tumor samples using the OncomineTM BRCA Research Assay on Personal Genome Machine Platform with Ion Reporter Software for sequencing data analysis. The presence of pathogenic mutations was confirmed by Sanger sequencing. Results: We found no BRCA2 mutation in the entire cohort. Four types of pathogenic mutations in BRCA1 (Ser454Ter, Gln541Ter, Arg1751Ter, and Gln1779AsnfsTer14) were detected in 8 unrelated patients (7.9%) belonging to serous and endometrioid carcinoma groups. Except for the c.1360_1361delAG (Ser454Ter) mutation in BRCA1 exon 11 that was somatic, the other mutations in exons 11, 20, and 22 were germline. Interestingly, the recurrent Arg1751Ter mutation in BRCA1 exon 20 appeared in 4 patients, suggesting that this is a founder mutation in Vietnamese patients. Conclusion: Mutational analysis of tumor tissue using next generation sequencing allowed the detection of both germline and somatic BRCA1/2 mutations. 相似文献
102.
103.
Objective To investigate the pathogenesis mechanism of radiation esophagitis from the perspective of mucosal regeneration and to determine whether it is associated with TGF-β1/p38MAPKs/FN signaling pathway. Methods The pathological analysis of esophageal specimens was performed by HE staining method. The expression of FN and TGF-β1 genes were observed by real time-PCR method, and the expression of tissue proteins TGF-β1, p38 and FN were detected by Western blot. Results The weights, food intakes and water intakes at the first week after the occurrence of radiation esophagitis were significantly decreased (P<0.05) and recovered at the fourth week. The esophageal mucosa was destructed at the first and second weeks, and the regeneration occurred in the fourth weeks; TGF-β1 and p38MAPK protein expression increased first and then decreased, while FN protein expression decreased first and then increased. Conclusion The TGF-β1/p38MAPK/FN signaling pathway may be involved in the process of mucosal repair. © 2020, CHINA RESEARCH ON PREVENTION AND TREATMENT. All rights reserved. 相似文献
104.
目的 研究长链非编码RNA (LncRNA) UCA1对肺癌细胞增殖、凋亡及放射敏感性影响及其机制。方法 运用qRT-PCR法检测肺癌细胞A549、H1299和人正常肺细胞HBE中UCA1、miR-513a-5p表达。将si-con组(转染si-con)、si-UCA1组(转染si-UCA1)、miR-513a-5p组(转染miR-513a-5p mimics)、miR-NC组(转染miR-NC)、IR+si-con组(转染si-con+照射)、IR+si-UCA1组(转染miR-NC+照射)、IR+miR-513a-5p组(转染miR-513a-5p mimics+照射)、IR+miR-NC组(转染miR-NC+照射)、IR+si-UCA1+anti-miR-513a-5p组(共转染si-UCA1和anti-miR-513a-5p+照射)均用脂质体法转染至A549、H1299细胞,然后部分组进行4Gy照射。MTT法检测各组细胞增殖,克隆形成实验检测细胞增敏比,流式细胞术检测各组细胞凋亡,双荧光素没报告基因检测实验检测各组细胞的荧光活性。结果 与HBE细胞相比,A549、H1299细胞中UCA1表达显著升高(P<0.05),miR-513a-5p表达显著降低(P<0.05)。抑制UCA1、过表达miR-513a-5p均可明显抑制A549、H1299细胞增殖、促进凋亡、提高放射敏感性(放射增敏比为1.897、2.146和1.615、1.872)。miR-513a-5p可抑制野生型UCA1细胞的荧光活性,且UCA1可负向调控miR-513a-5p的表达。抑制miR-513a-5p可逆转抑制UCA1对细胞的放射敏感性的增强作用。结论 抑制LncRNA UCA1可增强放射对肺癌细胞敏感性,其机制可能与靶向抑制miR-513a-5p有关。 相似文献
105.
背景与目的:不育α基序结构域和组氨酸/天冬氨酸残基双联体结构域包涵蛋白1(sterile alpha motif and histidine/aspartic acid domain-containing protein 1,SAMHD1)具有抑制多种肿瘤细胞生长的作用,但其调节肝细胞癌(hepatocellular carcinoma,HCC)细胞增殖的作用及机制尚未见报道。探究SAMHD1调控p27的表达对HCC细胞Huh7的增殖、凋亡和细胞周期的影响。方法:首先通过蛋白质印迹法(Western blot)检测正常肝细胞和不同类型HCC细胞中SAMHD1的表达情况。利用基因修饰技术构建过表达SAMHD1、dNTP酶活性位点突变体(SAMHD1-D207N)和磷酸化位点突变体(SAMHD1-T592E)的重组质粒,然后利用四甲基偶氮唑蓝(methyl thiazolyl tetrazolium,MTT)法检测过表达SAMHD1及其突变体或siRNA干扰沉默SAMHD1对HCC细胞增殖的影响,采用流式细胞术检测细胞周期与细胞凋亡情况。在癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库中分析SAMHD1和p27表达的相关性。结果:HCC细胞中SAMHD1表达上调,过表达SAMHD1、SAMHD1-D207N和SAMHD1-T592E可以抑制Huh7细胞增殖,细胞周期停滞在G 1 /G 0 期;相反,干扰SAMHD1后细胞增殖加快,细胞周期停滞在G 2 /M期。机制研究表明,SAMHD1上调细胞周期蛋白激酶抑制因子p27的表达。在HCC组织中,p27的表达与SAMHD1表达呈正相关。结论:过表达SAMHD1可以上调p27的表达,导致细胞周期停滞在G 1 /G 0 期,从而抑制HCC细胞增殖,这种抑制作用不依赖于其dNTP酶活性和磷酸化修饰。 相似文献
106.
107.
108.
目的:初步探讨mTOR抑制剂AZD2014对肝癌细胞的增殖抑制作用及其机制。方法:先采用CCK-8法检测不同浓度的AZD2014(10、100、500、1 000 nmol/L)对肝癌细胞增殖的作用,再分别采用荧光定量PCR和Western blot法检测肝癌细胞中含植物同源结构和环指域泛素样蛋白1(UHRF1)mRNA和蛋白的表达水平。结果:细胞增殖实验结果显示,10、100、500、1 000 nmol/L的AZD2014均可显著抑制肝癌细胞的增殖能力,抑制程度与其浓度呈正相关(P < 0.05);荧光定量PCR和Western blot检测结果显示,500和1 000 nmol/L的AZD2014可显著降低肝癌细胞内UHRF1 mRNA及蛋白的表达水平。结论:AZD2014可能通过抑制肝癌细胞内UHRF1的表达水平来抑制肝癌细胞的增殖能力。 相似文献
109.
《药学学报(英文版)》2020,10(5):799-811
Overexpression of adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) in cancer cells is known to cause multidrug resistance (MDR), which severely limits the clinical efficacy of chemotherapy. Currently, there is no FDA-approved MDR modulator for clinical use. In this study, rociletinib (CO-1686), a mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was found to significantly improve the efficacy of ABCG2 substrate chemotherapeutic agents in the transporter-overexpressing cancer cells in vitro and in MDR tumor xenografts in nude mice, without incurring additional toxicity. Mechanistic studies revealed that in ABCG2-overexpressing cancer cells, rociletinib inhibited ABCG2-mediated drug efflux and increased intracellular accumulation of ABCG2 probe substrates. Moreover, rociletinib, inhibited the ATPase activity, and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling of ABCG2. However, ABCG2 expression at mRNA and protein levels was not altered in the ABCG2-overexpressing cells after treatment with rociletinib. In addition, rociletinib did not inhibit EGFR downstream signaling and phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK). Our results collectively showed that rociletinib reversed ABCG2-mediated MDR by inhibiting ABCG2 efflux function, thus increasing the cellular accumulation of the transporter substrate anticancer drugs. The findings advocated the combination use of rociletinib and other chemotherapeutic drugs in cancer patients with ABCG2-overexpressing MDR tumors. 相似文献
110.
BackgroundImmunotherapy has made encouraging progress in the treatment of urothelial carcinoma, but only a small percentage of patients respond effectively to the immune checkpoint blockade (ICB). Our study aims to develop a classifier could effectively predict the response to ICB.MethodsSupport vector machines recursive feature elimination (SVM-RFE) algorithm was used to feature selection, then compared nine common binary classification algorithms through machine learning, we selected the classifier with the highest prediction performance (LASSO logistics classifier). Ten-fold cross-validation was used to avoid the overfitting effect.ResultsWe developed a classifier on a urothelial carcinoma cohort treated with PD-L1 inhibitor Atzolizumab (IMvigor210 cohort, n = 272) and calculated a tumor mutational burden-related LASSO score (TLS) using the LASSO algorithm, which was significantly correlated with Tumor mutational burden (TMB) and neoantigen burden. We validated the efficacy of TLS in predicting prognosis and immunotherapy benefit in internal (IMvigor210) and external validation set (TCGA-BLCA, n = 406), respectively.ConclusionsAfter in-depth analysis, we provide a new idea for stratified treatment of such patients, that is, patients with high TLS should use ICB and also may benefit from hormone therapy, while patients with low TLS respond poorly to ICB and maybe benefit from targeting TGFβ. 相似文献